Infinity Pharmaceuticals Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Infinity Pharmaceuticals saw a decline in short interest in February. As of February 12th, there was short interest totaling 575,400 shares, a decline of 18.4% from the January 28th total of 705,500 shares. Based on an average trading volume of 3,460,000 shares, the short-interest ratio is currently 0.2 days.
View Infinity Pharmaceuticals' Short Interest.

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Infinity Pharmaceuticals.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Monday, November, 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biotechnology company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.22 million. Infinity Pharmaceuticals had a negative net margin of 2,592.65% and a negative trailing twelve-month return on equity of 1,358.77%.
View Infinity Pharmaceuticals' earnings history.

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INFI stock has increased by 168.3% and is now trading at $2.71.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12-month target prices for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $9.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of INFI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.45%), BlackRock Inc. (1.52%), Baker BROS. Advisors LP (0.81%), Northern Trust Corp (0.25%), Callan Capital LLC (0.11%) and JPMorgan Chase & Co. (0.06%).
View institutional ownership trends for Infinity Pharmaceuticals.

INFI stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, and Northern Trust Corp.
View insider buying and selling activity for Infinity Pharmaceuticals or view top insider-selling stocks.

INFI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Callan Capital LLC, JPMorgan Chase & Co., Private Wealth Advisors Inc., and BlackRock Inc..
View insider buying and selling activity for Infinity Pharmaceuticals or or view top insider-buying stocks.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFI stock can currently be purchased for approximately $2.71.

Infinity Pharmaceuticals has a market capitalization of $174.00 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

Infinity Pharmaceuticals employs 25 workers across the globe.

The official website for Infinity Pharmaceuticals is www.infi.com.

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]